# US 2015/0087823 A1 · Trans-2-decenoic acid derivative and drug containing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0087823 A1
- Document ID: US20150087823A1
- Status: Published application
- Kind: A1
- Application number: 14/395,241
- Filed: 2013-04-26
- Published: 2015-03-26
- Earliest claimed: 2012-04-27
- Assignees: Nippon Zoki Pharmaceutical Co., Ltd.; Nagoya Industrial Science Research Institute
- Applicants: Nippon Zoki Pharmaceutical Co., Ltd.; Nagoya Industrial Science Research Institute
- Inventors: Munekazu Iinuma; Shoei Furukawa; Mitsuru Naiki; Tomonori Matsumoto; Kunihiko Higashiura
- Web page: https://patentgrep.com/patent/US20150087823A1

## CPC

- C07D 295/185: from aliphatic carboxylic acids
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/16: with acylated ring nitrogen atom
- C07D 211/18: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- C07D 211/30: with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D 211/44: attached in position 4
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 211/48: having an acyclic carbon atom attached in position 4
- C07D 211/58: attached in position 4
- C07D 211/62: attached in position 4
- C07D 211/74: Oxygen atoms
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 243/08: not condensed with other rings
- C07D 277/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 295/18: by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical agent containing the compound as an active ingredient. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt, which is the compound of the present invention, is specifically represented by the general formula (I): wherein X is a substituent such as a 1-pyrrolidyl, a 3-thiazolizyl, or a piperidino, and the compound is highly useful as a pharmaceutical agent, such as a prophylactic or therapeutic agent for a peripheral nerve disorder induced by administration of an anticancer agent, a prophylactic or therapeutic agent for neurodegenerative diseases or mental diseases such as dementia, Alzheimer's disease, Parkinson's disease, diabetic neuropathy, depression, glaucoma, or autistic disorder spectrum, a therapeutic or repairing agent for spinal cord injury, analgesics against various pain diseases, or the like.

## Claims

### Claim 1

A trans-2-decenoic acid derivative represented by the following general formula (I′) or a pharmaceutically acceptable salt thereof:
wherein X′ is:
(a) a 1-pyrrolidyl substituted with carboxyl or alkoxycarbonyl,
(b) a 3-thiazolidyl,
(c) a piperidino substituted with alkyl, oxo, hydroxy, alkoxy, carboxyl, alkoxycarbonyl, alkylamino, alkylaminoalkyl, phenyl, carboxyalkyl, alkoxycarbonylalkyl, cyano, or halogenophenyl,
(d) a thiomorpholino,
(e) a 1-piperazyl which may be substituted with alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkylaminoalkyl, cycloalkyl, piperidinoalkyl, phenylalkyl, pyridyl, pyrimidyl, carboxyphenylalkyl or alkoxycarbonylphenylalkyl,
(f) a 1-piperazyl substituted with a phenyl which may be substituted with alkylamino, halogen, alkoxy, alkyl, hydroxy, carboxyalkoxy or alkoxycarbonylalkoxy,
(g) a 1,4-diazepanyl which may be substituted with alkyl or alkylaminoalkyl, or
(h) a carboxymorpholino.

### Claim 2 (depends on 1)

The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein X′ is a 1-pyrrolidyl substituted with carboxyl or alkoxycarbonyl.

### Claim 3 (depends on 1)

The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein X′ is a 3-thiazolidyl, a thiomorpholino or a carboxymorpholino.

### Claim 4 (depends on 1)

The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein X′ is a piperidino substituted with alkyl, oxo, hydroxy, alkoxy, carboxyl, alkoxycarbonyl, alkylamino, alkylaminoalkylphenyl, carboxyalkyl, alkoxycarbonylalkyl, cyano or halogenophenyl.

### Claim 5 (depends on 1)

The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein X′ is a 1-piperazyl which may be substituted with alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkylaminoalkyl, cycloalkyl, piperidinoalkyl, phenylalkyl, pyridyl, pyrimidyl, carboxyphenylalkyl or alkoxycarbonylphenylalkyl.

### Claim 6 (depends on 1)

The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein X′ is a 1-piperazyl substituted with a phenyl which may be substituted with alkylamino, halogen, alkoxy, alkyl, hydroxy, carboxyalkoxy or alkoxycarbonylalkoxy.

### Claim 7 (depends on 1)

The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein X′ is a 1,4-diazepanyl which may be substituted with alkyl or alkylaminoalkyl.

### Claim 8

A pharmaceutical agent comprising, as an active ingredient, at least one member of a trans-2-decenoic acid derivative represented by the following general formula (I) and a pharmaceutically acceptable salt thereof:
wherein X is:
(a) a 1-pyrrolidyl substituted with carboxyl or alkoxycarbonyl,
(b) a 3-thiazolidyl,
(c) a piperidino substituted with alkyl, oxo, hydroxy, alkoxy, carboxyl, alkoxycarbonyl, alkylamino, alkylaminoalkyl, phenyl, carboxyalkyl, alkoxycarbonylalkyl, cyano, or halogenophenyl,
(d) a thiomorpholino,
(e) a 1-piperazyl which may be substituted with alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkylaminoalkyl, cycloalkyl, piperidinoalkyl, phenylalkyl, pyridyl, pyrimidyl, carboxyphenylalkyl or alkoxycarbonylphenylalkyl,
(f) a 1-piperazyl substituted with a phenyl which may be substituted with alkylamino, halogen, alkoxy, alkyl, hydroxy, carboxyalkoxy or alkoxycarbonylalkoxy,
(g) a 1,4-diazepanyl which may be substituted with alkyl or alkylaminoalkyl, or
(h) a carboxymorpholino.

### Claim 9 (depends on 8)

The pharmaceutical agent according to claim 8, wherein the pharmaceutical agent is a prophylactic agent or therapeutic agent for peripheral nerve disorders induced by administration of a drug comprising at least one anti-cancer agent.

### Claim 10 (depends on 8)

The pharmaceutical agent according to claim 8, wherein the pharmaceutical agent is a prophylactic agent or therapeutic agent for neurodegenerative diseases.

### Claim 11 (depends on 8)

The pharmaceutical agent according to claim 8, wherein the pharmaceutical agent is a prophylactic agent or therapeutic agent for mental diseases.

### Claim 12 (depends on 11)

The pharmaceutical agent according to claim 11, wherein the mental diseases are depression, anxiety disorders (neuroses), or autistic disorder spectrum.

### Claim 13 (depends on 8)

The pharmaceutical agent according to claim 8, wherein the pharmaceutical agent is an analgesic against pain diseases.

### Claim 14 (depends on 8)

The pharmaceutical agent according to claim 8, wherein the pharmaceutical agent is an injectable preparation.

### Claim 15 (depends on 8)

The pharmaceutical agent according to claim 8, wherein the pharmaceutical agent is an oral preparation.

### Claim 16 (depends on 8)

The pharmaceutical agent according to claim 8, wherein the pharmaceutical agent is an external agent.
